+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2019

  • ID: 4894143
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 707 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 1st Bio Therapeutics Inc
  • Biogen Inc
  • Eisai Co Ltd
  • K Pharma Inc
  • Neurimmune Holding AG
  • Relmada Therapeutics Inc
  • MORE
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2019, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape.

Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate. Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 8, 24, 23, 3, 116, 33 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 34 and 10 molecules, respectively.

Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 1st Bio Therapeutics Inc
  • Biogen Inc
  • Eisai Co Ltd
  • K Pharma Inc
  • Neurimmune Holding AG
  • Relmada Therapeutics Inc
  • MORE
Introduction
Amyotrophic Lateral Sclerosis - Overview
Amyotrophic Lateral Sclerosis - Therapeutics Development
Amyotrophic Lateral Sclerosis - Therapeutics Assessment
Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development
Amyotrophic Lateral Sclerosis - Drug Profiles
Amyotrophic Lateral Sclerosis - Dormant Projects
Amyotrophic Lateral Sclerosis - Discontinued Products
Amyotrophic Lateral Sclerosis - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Amyotrophic Lateral Sclerosis - Pipeline by 1st Bio Therapeutics Inc, H2 2019
Amyotrophic Lateral Sclerosis - Pipeline by AB Science SA, H2 2019
Amyotrophic Lateral Sclerosis - Pipeline by Above and Beyond Concierge Therapeutics LLC, H2 2019
Amyotrophic Lateral Sclerosis - Pipeline by AC Immune SA, H2 2019
Amyotrophic Lateral Sclerosis - Pipeline by Acceleron Pharma Inc, H2 2019
Amyotrophic Lateral Sclerosis - Pipeline by Aclipse One Inc, H2 2019
Amyotrophic Lateral Sclerosis - Pipeline by AcuraStem Inc, H2 2019
Amyotrophic Lateral Sclerosis - Pipeline by Affichem SA, H2 2019

List of Figures
Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3
  • 1st Bio Therapeutics Inc
  • AB Science SA
  • Above and Beyond Concierge Therapeutics LLC
  • AC Immune SA
  • Acceleron Pharma Inc
  • Aclipse One Inc
  • AcuraStem Inc
  • Affichem SA
  • AL-S Pharma AG
  • Alexion Pharmaceuticals Inc
  • Alsonex Pty Ltd
  • Amylyx Pharmaceutical Corp
  • Anavex Life Sciences Corp
  • Anelixis Therapeutics LLC
  • Anida Pharma Inc
  • Ankar Pharma SL
  • Annexon Inc
  • Apic Bio Inc
  • Apogenix AG
  • ApoPharma Inc
  • Aquinnah Pharmaceuticals Inc
  • ArmaGen Inc
  • ArunA Biomedical Inc
  • Athira Pharma Inc
  • Autophagy Neurotherapeutics Inc
  • Avanir Pharmaceuticals Inc
  • AveXis Inc
  • Axovant Gene Therapies Ltd
  • AZTherapies Inc
  • Bach Pharma Inc
  • Bausch Health Companies Inc
  • Biogen Inc
  • Biohaven Pharmaceutical Holding Company Ltd
  • BioHealthonomics Inc
  • Bioinova sro
  • BrainStorm Cell Therapeutics Inc
  • Bruschettini Srl
  • Calico LLC
  • CavoGene LifeSciences
  • CellCure
  • Cerion LLC
  • Chaperone Therapeutics Inc
  • Chemigen LLC
  • CholesteniX Ltd
  • Chronos Therapeutics Ltd
  • Chugai Pharmaceutical Co Ltd
  • Clene Nanomedicine Inc
  • Cogentis Therapeutics Inc
  • Collaborative Medicinal Development LLC
  • Constant Therapeutics LLC
  • Corcept Therapeutics Inc
  • Corestem Inc
  • CSPC NBP Pharmaceutical Co Ltd
  • Curatis AG
  • CuroNZ Ltd
  • Cytokinetics Inc
  • Daiichi Sankyo Co Ltd
  • Denali Therapeutics Inc
  • Disarm Therapeutics Inc
  • Eikonizo Therapeutics Inc
  • Eisai Co Ltd
  • Elysium Health Inc
  • Emerald Health Sciences Inc
  • EnhanX Biopharm Inc
  • Epigen Biosciences Inc
  • Everfront Biotech Inc
  • Gemac SA
  • Gene Therapy Research Institution Co Ltd
  • Genentech Inc
  • Genervon Biopharmaceuticals LLC
  • GeNeuro SA
  • Genuv Inc
  • Gilead Sciences Inc
  • Glialogix Inc
  • GlyTag LLC
  • GNT Pharma Co Ltd
  • Grifols SA
  • Guangzhou Magpie Pharmaceutical Co Ltd
  • Helixmith Co Ltd
  • Hemostemix Inc
  • Herantis Pharma Plc
  • Immunity Pharma Ltd
  • Implicit Bioscience Ltd
  • ImStar Therapeutics Inc
  • Ionis Pharmaceuticals Inc
  • Iron Horse TherapeuticsInc
  • J2H Biotech
  • Junaxo Inc
  • K Pharma Inc
  • K-Pax Pharmaceuticals Inc
  • K-Stemcell Co Ltd
  • Kadimastem Ltd
  • Keapstone Therapeutics Ltd
  • KineMed Inc
  • Klogene Therapeutics Inc
  • Kringle Pharma Inc
  • Kyorin Pharmaceutical Co Ltd
  • Kyowa Kirin Co Ltd
  • Lascco SA
  • Lauren Sciences LLC
  • LifeSplice Pharma LLC
  • Locana Inc
  • Maas Biolab
  • MedDay SA
  • MeiraGTx Holdings Plc
  • Meta-IQ ApS
  • MetVital Inc
  • MimeTech Srl
  • Miragen Therapeutics Inc
  • Mitoconix Bio Ltd
  • MitoDys Therapeutics Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Nanna Therapeutics Ltd
  • NeuExcell Therapeutics Inc
  • Neuracle Science Co Ltd
  • Neurimmune Holding AG
  • Neurodegeneration Therapeutics Inc
  • Neurodyn Life Sciences Inc
  • Neuropore Therapies Inc
  • NeuroSense Therapeutics Ltd
  • Neurotune AG
  • New Biotic Inc
  • Novartis AG
  • NuNerve Pty Ltd
  • OptiKira LLC
  • Orbis Biosciences Inc
  • Orion Corp
  • Orphazyme A/S
  • Orpheris Inc
  • Oxford BioMedica Plc
  • Pfizer Inc
  • Pharnext SA
  • Plex Pharmaceuticals Inc
  • Priavoid GmbH
  • Prilenia Therapeutics Development Ltd
  • ProMIS Neurosciences Inc
  • Prothena Corp Plc
  • Prous Institute for Biomedical Research SA
  • PTC Therapeutics Inc
  • Q Therapeutics Inc
  • QurAlis Corp
  • Ra Pharmaceuticals Inc
  • RASRx LLC
  • Relmada Therapeutics Inc
  • reMYND NV
  • Retrotope Inc
  • Revalesio Corp
  • Sangamo Therapeutics Inc
  • Seneca Biopharma Inc
  • Shinkei Therapeutics LLC
  • Spedding Research Solutions SAS
  • Stealth BioTherapeutics Corp
  • Talon Pharmaceutical Services Inc
  • Thera Neuropharma Inc
  • Theratome Bio Inc
  • TikoMed AB
  • Tiziana Life Sciences Plc
  • Tolerion Inc
  • Tranquis Therapeutics Inc
  • Treeway BV
  • Trucode Gene Repair Inc
  • Ultragenyx Pharmaceutical Inc
  • UniQure NV
  • Verge Genomics Inc
  • Voyager Therapeutics Inc
  • Wave Life Sciences Ltd
  • Xalud Therapeutics Inc
  • Xcelthera INC
  • Xonovo Inc
  • Yooyoung Pharm Co Ltd
  • Yumanity Therapeutics
  • ZZ Biotech LLC
Note: Product cover images may vary from those shown
Adroll
adroll